» Articles » PMID: 20378603

Cystic Fibrosis and Survival to 40 Years: a Case-control Study

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2010 Apr 10
PMID 20378603
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical course of patients with cystic fibrosis (CF) is variable and probably determined by many interacting factors. We aimed to examine the influence of early social and clinical factors on long-term survival. A case-control study of adult CF patients was used to compare long-term survivors (aged ≥ 40 yrs) with patients who died before reaching 30 yrs of age. Each case (n = 78) was matched by birth date with at least one control (n = 152), after exclusion of "late diagnosis" patients. Probability-weighted logistic regression models were used to identify influences on survival. Factors resulting in increased probabilities of survival included high body mass index (OR 1.76, 95% CI 1.40-2.22), forced expiratory volume in 1 s (OR per 5% increase 1.54, 95% CI 1.32-1.80), and forced vital capacity (OR per 5% increase 1.54, 95% CI 1.33-1.78) at transfer to the adult clinic and the exclusive use of oral antibiotics (OR 8.31, 95% CI 3.02-22.88). Factors resulting in decreased probabilities of survival were Pseudomonas aeruginosa acquisition (OR 0.18, 95% 0.05-0.65) or pneumothorax before transfer to the adult clinic (OR 0.02, 95% CI 0.004-0.08) and referral from a paediatric clinic in a deprived area (OR 0.13, 95% CI 0.04-0.38). Long-term survival is associated with the clinical features present by the time of referral to an adult clinic. Even "early-diagnosis" disease appears to have different phenotypes, possibly independent of CF gene function, that have different survival patterns.

Citing Articles

Factors associated with cystic fibrosis mortality before the age of 30: retrospective analysis of a cohort in southern Brazil.

Conto J, Dalcin P, Ziegler B Braz J Med Biol Res. 2024; 57:e13476.

PMID: 39194031 PMC: 11349154. DOI: 10.1590/1414-431X2024e13476.


The determinants of survival among adults with cystic fibrosis-a cohort study.

Durda-Masny M, Gozdzik-Spychalska J, John A, Czainski W, Strozewska W, Pawlowska N J Physiol Anthropol. 2021; 40(1):19.

PMID: 34749804 PMC: 8573904. DOI: 10.1186/s40101-021-00269-7.


Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.

Bensman T, Wang J, Jayne J, Fukushima L, Rao A, DArgenio D Antimicrob Agents Chemother. 2017; 61(10).

PMID: 28784670 PMC: 5610479. DOI: 10.1128/AAC.00988-17.


A murine model of early Pseudomonas aeruginosa lung disease with transition to chronic infection.

Bayes H, Ritchie N, Irvine S, Evans T Sci Rep. 2016; 6:35838.

PMID: 27804985 PMC: 5090221. DOI: 10.1038/srep35838.


Evaluating outpatient transition clinics: a mixed-methods study protocol.

Sattoe J, Peeters M, Hilberink S, Ista E, Van Staa A BMJ Open. 2016; 6(8):e011926.

PMID: 27566639 PMC: 5013382. DOI: 10.1136/bmjopen-2016-011926.